Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease ...

Investing.com -- Despite record-high stock prices, investor sentiment has taken a decidedly bearish turn in recent weeks, a development that Yardeni Research views as a contrarian bullish signal.